FDA: Type 2 Diabetes Drug Approved as Add-On to Diet, Exercise

The US Food and Drug Administration has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor Steglatro (ertugliflozin) for the improvement of glycemic control in adults with type 2 diabetes.

The drug is available in once-daily 5 mg and 15 mg oral tablets and is approved as an add-on treatment to diet and exercise.
____________________________________________________________________________

RELATED CONTENT
FDA Approves New Drug for Dangerously Low BP
FDA Approves New Glaucoma Treatment
____________________________________________________________________________

In addition, the approval extends to 2 ertugliflozin combination treatments, once-daily Steglujan (ertugliflozin and sitagliptin) and twice-daily Segluromet (ertugliflozin and metformin).

Steglujan is available in doses of 5 mg ertugliflozin/100 mg sitagliptin and 15 mg/100 mg. Segluromet is available in doses of 2.5 mg ertugliflozin/500 mg metformin, 2.5 mg/1000 mg, 7.5 mg/500 mg, and 7.5 mg/1000 mg.

—Christina Vogt

Reference:

Novel drug approvals for 2017. US Food and Drug Administration. December 20, 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm. Accessed December 22, 2017.